Rectal cancer stage III – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:21 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Rectal cancer stage III – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study comparing treatment with or without tislelizumab for patients with locally advanced rectal cancer to see if surgery can be avoided https://clinicaltrials.eu/trial/study-comparing-treatment-with-or-without-tislelizumab-for-patients-with-locally-advanced-rectal-cancer-to-see-if-surgery-can-be-avoided/ Thu, 30 Apr 2026 13:08:48 +0000 https://clinicaltrials.eu/trial/study-comparing-treatment-with-or-without-tislelizumab-for-patients-with-locally-advanced-rectal-cancer-to-see-if-surgery-can-be-avoided/ This study is looking at Locally Advanced Rectal Cancer, which is cancer in the lower part of the large intestine that has grown into deeper layers of the bowel wall or has spread to nearby lymph nodes but has not spread to distant parts of the body. The treatment being tested is called Tislelizumab, which is also known by its code name BGB-A317. This medication is given through an intravenous infusion, which means it is delivered directly into a vein over a period of time. The study will compare two groups of patients: one group will receive standard total neoadjuvant treatment, which is a combination of chemotherapy and radiation therapy given before surgery, while the other group will receive the same treatment plus Tislelizumab.

The purpose of this study is to compare how long patients in both groups can avoid having a major surgery called TME (total mesorectal excision) over a three-year period. TME is a surgical procedure to remove the rectum and surrounding tissue. Patients in the study will receive their assigned treatment before any surgery is planned. The maximum daily dose of Tislelizumab will be 150 milligrams, with a maximum total dose of 1200 milligrams over a treatment period of up to 16 weeks. The study will also look at other outcomes such as how well the tumor responds to treatment, survival rates, side effects, and how the treatment affects patients’ quality of life.

During the study, patients will be randomly assigned to one of the two treatment groups. Both groups will receive chemotherapy and radiation therapy as part of their neoadjuvant treatment, which is treatment given before the main treatment to help shrink the tumor. One group will also receive Tislelizumab along with the standard treatment. Patients will be monitored throughout the treatment period and for several years afterward to measure the effectiveness of the treatment and any side effects that may occur. The study will collect tissue samples from the initial colonoscopy to confirm the diagnosis and for research purposes.

]]> Study on Oxaliplatin and Capecitabine for Patients with Locally Advanced Rectal Cancer https://clinicaltrials.eu/trial/study-on-oxaliplatin-and-capecitabine-for-patients-with-locally-advanced-rectal-cancer/ Wed, 29 Apr 2026 15:01:03 +0000 https://clinicaltrials.eu/trial/study-on-oxaliplatin-and-capecitabine-for-patients-with-locally-advanced-rectal-cancer/ This clinical trial is focused on studying a type of cancer called locally advanced rectal cancer, specifically a form known as adenocarcinoma that occurs in the middle or lower part of the rectum. The study is investigating a treatment approach that does not involve surgery. Instead, it uses a combination of medications and therapies to treat the cancer. The medications being studied are Oxaliplatin and Capecitabine, which are both chemotherapeutic drugs. These drugs are used to kill cancer cells or stop them from growing and spreading.

The purpose of the study is to determine if this non-surgical treatment approach is effective in preventing the cancer from coming back in other parts of the body. Participants in the study will receive a combination of treatments, including Induction Chemotherapy (ICT) and Chemo-Radiotherapy (CRT), followed by a period of close monitoring without surgery. The study will also look at various markers in the blood and tissue to understand how the treatment affects the cancer and the surrounding tissue.

Throughout the study, participants will be closely monitored to assess their response to the treatment. The study aims to evaluate the rate of complete response, meaning the cancer is no longer detectable, as well as the overall survival and quality of life of the participants. The study will also track any recurrence of the cancer and the ability to preserve the organs affected by the cancer. This research hopes to provide valuable insights into the effectiveness of non-surgical treatments for locally advanced rectal cancer.

]]> Study on Atezolizumab for Patients with High-Risk Stage II or Stage III Colorectal Cancer Not Eligible for Oxaliplatin Chemotherapy https://clinicaltrials.eu/trial/study-on-atezolizumab-for-patients-with-high-risk-stage-ii-or-stage-iii-colorectal-cancer-not-eligible-for-oxaliplatin-chemotherapy/ Wed, 29 Apr 2026 15:00:33 +0000 https://clinicaltrials.eu/trial/study-on-atezolizumab-for-patients-with-high-risk-stage-ii-or-stage-iii-colorectal-cancer-not-eligible-for-oxaliplatin-chemotherapy/ This clinical trial is focused on studying a type of cancer called colorectal cancer, specifically in patients who have a high risk of recurrence or have stage III disease. These patients have tumors that are either MSI-high (microsatellite instability-high) or MMR-deficient (mismatch repair-deficient), which are specific characteristics of the cancer cells. The study is for those who cannot receive or choose not to receive a common chemotherapy treatment known as oxaliplatin. The main goal of the study is to see if a medication called atezolizumab, also known by its code name RO5541267, can help improve the chances of staying cancer-free for three years after treatment.

The treatment being tested is atezolizumab, which is given as an infusion, meaning it is administered directly into the bloodstream through a vein. This study will also include a comparison with a placebo, which is a substance with no active medication, to see how effective atezolizumab is on its own. The study will last for up to 12 months, during which participants will receive the treatment and have regular check-ups to monitor their health and the status of their cancer.

Participants in the study will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on whether atezolizumab can be a beneficial treatment option for patients with this specific type of colorectal cancer who are not suitable for standard chemotherapy. The results could potentially lead to new treatment options for these patients in the future.

]]> Study of Regorafenib and Nivolumab with radiotherapy for patients with stage II-III rectal cancer before surgery https://clinicaltrials.eu/trial/study-of-regorafenib-and-nivolumab-with-radiotherapy-for-patients-with-stage-ii-iii-rectal-cancer/ Wed, 29 Apr 2026 15:00:02 +0000 https://clinicaltrials.eu/trial/study-of-regorafenib-and-nivolumab-with-radiotherapy-for-patients-with-stage-ii-iii-rectal-cancer/ This study focuses on patients with stage II-III rectal cancer that is locally advanced. The treatment combines three different approaches: two medications – nivolumab and regorafenib – along with short-course radiotherapy. Both medications are given to patients before and after the radiotherapy treatment.

Nivolumab is administered through an intravenous infusion (through a vein), while regorafenib is taken as tablets by mouth. The study aims to determine if this combination of treatments can achieve a complete response in patients whose tumors have specific characteristics (referred to as pMMR/MSS tumors). A complete response means that there are no signs of cancer remaining after the treatment.

During the study, patients receive nivolumab infusions at a maximum daily dose of 240 mg, with a total maximum dose of 1200 mg over 5 weeks. Regorafenib tablets are given at a maximum daily dose of 60 mg, with a total maximum dose of 2040 mg over 34 weeks. Patients undergo regular medical examinations and imaging tests throughout the treatment period to monitor their response to the therapy.

]]> Study on Short-Course Radiotherapy and Chemotherapy with Fluorouracil, Irinotecan, and Oxaliplatin for Patients with Locally Advanced Rectal Cancer https://clinicaltrials.eu/trial/study-on-short-course-radiotherapy-and-chemotherapy-with-fluorouracil-irinotecan-and-oxaliplatin-for-patients-with-locally-advanced-rectal-cancer/ Wed, 29 Apr 2026 14:57:37 +0000 https://clinicaltrials.eu/trial/study-on-short-course-radiotherapy-and-chemotherapy-with-fluorouracil-irinotecan-and-oxaliplatin-for-patients-with-locally-advanced-rectal-cancer/ This clinical trial is focused on studying a treatment approach for locally advanced rectal cancer. The treatment being tested involves a combination of therapies, starting with a short course of radiotherapy followed by a chemotherapy regimen known as FOLFOXIRI. This chemotherapy regimen includes the drugs Fluorouracil, Irinotecan, Oxaliplatin, and Calcium Levofolinate. These medications are administered through an intravenous infusion, which means they are given directly into a vein.

The purpose of the study is to evaluate the effectiveness of this treatment combination in achieving a complete response, meaning the absence of cancer cells in the tissue removed during surgery. Participants in the study will first receive radiotherapy, which uses high-energy rays to target and kill cancer cells. After this, they will undergo several cycles of chemotherapy with the FOLFOXIRI regimen to further reduce the cancer before surgery. The study aims to determine how well this approach works in treating the cancer and to monitor any side effects that may occur during the treatment process.

Throughout the study, participants will be closely monitored by healthcare professionals to assess their response to the treatment and to ensure their safety. The study will also collect information on the overall health and quality of life of the participants, as well as any changes in their condition. This information will help researchers understand the potential benefits and risks of using this treatment approach for locally advanced rectal cancer.

]]> Study Comparing Short-Course Radiotherapy and Drug Combination for Older Patients with Locally Advanced Rectal Cancer https://clinicaltrials.eu/trial/study-comparing-short-course-radiotherapy-and-drug-combination-for-older-patients-with-locally-advanced-rectal-cancer/ Wed, 29 Apr 2026 14:25:30 +0000 https://clinicaltrials.eu/trial/study-comparing-short-course-radiotherapy-and-drug-combination-for-older-patients-with-locally-advanced-rectal-cancer/ This clinical trial is focused on studying treatments for locally advanced rectal cancer in older patients. The trial compares two treatment approaches: short-course radiotherapy (SCRT) followed by surgery, with or without additional chemotherapy, and total neoadjuvant therapy (TNT), which involves a combination of treatments given before surgery. The main goal is to determine which approach offers a better balance between effectiveness and safety for older patients.

Participants in the study will receive various medications as part of their treatment. These include Capecitabine, Oxaliplatin, and Fluorouracil, which are commonly used in cancer treatment. Additionally, supportive medications such as Ondansetron, Dexamethasone, Folinic Acid, and Metoclopramide may be administered to help manage side effects and improve the overall treatment experience. Some patients may receive a placebo as part of the study design.

The study will follow participants over a period of time to assess outcomes such as overall survival, progression-free survival, and the occurrence of side effects. The trial aims to provide valuable information on the best treatment strategy for older patients with this type of cancer, ultimately helping to improve their quality of life and treatment outcomes.

]]>